Congress funds long-neglected fibroid research, targeting racial health disparities

What it does

This bill directs the federal government to expand research into uterine fibroids, establish a database tracking Medicaid coverage of fibroid treatments, and launch public education campaigns about the condition—particularly targeting minority women, who bear a disproportionate disease burden. It authorizes $30 million annually for research (2026–2030) and open-ended funding for education and provider outreach, with no new restrictions on any party.

Why we flagged it

The bill is a straightforward authorization for federal research, data collection, and public education on a neglected disease with documented racial health disparities. It contains no deregulation, liability shields, tax carve-outs, or private giveaways—only appropriations and coordination directives.

What the text implies

• The bill's emphasis on racial disparities and early-onset fibroids in Black women may drive future clinical trial recruitment and treatment-development priorities toward underserved populations, potentially shifting pharmaceutical R&D incentives.
• Mandated Medicaid data collection (Section 4) will create the first systematic federal picture of fibroid treatment patterns and costs across states, which could inform future coverage policy or reimbursement decisions.
• Authorization of 'such sums as may be necessary' for education (Sections 5–6) gives HHS discretion to scale campaigns without returning to Congress, enabling rapid response to emerging evidence or disparities.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

The bill addresses a significant public-health gap: uterine fibroids affect millions of women, cause substantial morbidity and economic loss, yet receive minimal federal research funding ($17M in 2019, ranked 243rd of 292 conditions). The bill funds research into underexplored treatments, mandates data collection on disparities, and requires education targeting Black and minority women who experience more severe disease. No provisions restrict citizen rights, impose costs, or create liability sh

Who stands to gain

• National Institutes of Health (research funding)
• Academic medical centers and research institutions (research grants)
• Nonprofit organizations and consumer groups (education/dissemination contracts)
• Medical device and pharmaceutical companies (potential market expansion if new treatments are develo

Named in the bill

Department of Health and Human Services (HHS), National Institutes of Health (NIH), Medicaid, Children's Health Insurance Program (CHIP), Agency for Healthcare Research and Quality (AHRQ), FDA (Federal Food, Drug, and Cosmetic Act reference)

Where it stands

77 cosponsors: 77 Democrats.

• Jul 15, 2025 — Introduced · Congress.gov: “Introduced in House”
• Jul 15, 2025 — Referred to House Committee on Energy and Commerce · Congress.gov: “Referred to the House Committee on Energy and Commerce”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.